跳到正文
制药经理人· GxP知识岛·· 2 天前AI 评分74

FDA 公布第一三共欧洲制剂厂 483 观察报告,三项观察涉及手动积分、OOS 调查与设备清洁

FDA 483:第一三共制剂工厂,手动积分!

AI 导读

FDA 公布第一三共欧洲公司德国 Pfaffenhofen 制剂厂的 Form FDA 483 观察报告(FEI 3003282622),该报告在 2025 年 7 月 14 日至 18 日检查后共列出三项观察。

正文

近日,FDA公布了第一三共欧洲制剂工厂(Daiichi Sankyo Europe GmbH)的483观察报告,列3项观察。

三项观察分别落在实验室记录、偏差与超标(OOS)调查、设备清洁与维护。第1项的核心是 Empower 色谱系统的手动积分:既无程序规定,也无审计追踪理由,更无授权记录。原文举例称,某产品放行数据中,约 (b)(4)% 的进样被手动积分。

第2项指向调查深度。压片粘冲偏差 200007918 启动后,未确定任何明确的根本原因;两起 OOS 调查(200008934、200010548)把「用了两片而不是一片」当作结论,却无分析员访谈记录支撑,纠正措施也只是重新培训当事分析员,未扩展到其他质量控制人员,也未针对根本原因建立预防措施。

第3项来自2025年7月14日的现场巡视:设备外表面、垫圈上留有明显残留,设备却被记录为已清洁;压片冲模的凹字内残留未清,另有冲头出现凹痕与缺口。

图1 FDA 483 原件第1页(观察1,FEI 3003282622,2025年7月18日签发,共5页)

Inspection Details

检查基本信息

Firm / 企业

Daiichi Sankyo Europe GmbH 第一三共欧洲公司(第一三共株式会社旗下)

Address / 地址

Luitpoldstr. 1

City, State and Zip Code, Country / 城市、州、邮编、国家

Pfaffenhofen A.D. Ilm, Bavaria, 85276, Germany

FEI Number / FEI 号

3003282622

Dates of Inspection / 检查日期

2025年7月14日–18日

Type of Establishment Inspected / 受检设施类型

Drug Product Manufacturer(药品制剂生产商)

Issued To / 收件人

Matthias Kuehn, Head of Europe Plant Management(欧洲工厂管理负责人)

District Office / 地区办公室

12420 Parklawn Drive, Room 2032, Rockville, MD 20857

Issued / 签发

2025年7月18日 检查员 Joseph A. Piechocki(Investigator)

说明:原件每页下部均印有“AMENDMENT 1”,应系本次观察项的修正版;签署栏只有检查员签字,无地区主任签名。本稿按原件编号与版式照录。

OBSERVATION 1

观察1:实验室记录未包含检测所得的完整数据(211.194(a))

Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.

实验室记录未包含为确保符合既定规格与标准所必需的全部检测、检查与含量测定所得的完整数据。

Specifically,

具体而言:

A. There is no procedure that describes the appropriate use of manual integration for acquired data within the Empower chromatography system nor do manual integration events require explanation to ensure complete rationale for use. For example, during the review of the release data supporting (b)(4) mg Batch (b)(4)(b)(4) specific test samples chromatograms (and (b)(4) test sample overall within the sample set) contained manually integrated peaks with no reason provided within the audit trail, nor was there documented authorization to perform this manual integration.

A.没有程序描述 Empower 色谱系统中采集数据手动积分的恰当用法,手动积分事件也不要求给出解释以确保使用理由完整。例如,在审阅支持 (b)(4) mg 批 (b)(4) 放行的数据时,(b)(4) 个特定检测样品的色谱图(以及该样品集中共 (b)(4) 个检测样品)存在手动积分的峰,审计追踪中未给出任何理由,也没有记录在案的授权。

In addition, during the review of chromatographic results obtained within Empower within the project folder “uplc 0251 a 04”, including results supporting the release testing of (b)(4) drug products, approximately (b)(4)% of the individual injections made had been manually integrated.

此外,在审阅 Empower 中项目文件夹“uplc 0251 a 04”内的色谱结果时(其中包括支持 (b)(4) 个药品放行检测的结果),约 (b)(4)% 的进样被手动积分。

B. Records related to analytical testing do not include all the information related to the execution of the test. For example, test methods K-PA 0251_I_HPLC1 and K-PA 0251_I_HPLC2 are used for assay, content uniformity, and related substance determination of (b)(4) drug products for the US market. The executed laboratory records do not include complete information related to the execution of the test, which includes the following:

B.与分析检测有关的记录未包含与检测实施有关的全部信息。例如,检测方法 K-PA 0251_I_HPLC1 与 K-PA 0251_I_HPLC2 用于 (b)(4) 个销往美国药品的含量、含量均匀度与有关物质测定。已执行的实验室记录未包含与检测实施有关的完整信息,具体包括:

1. Mobile phases and solutions used for testing do not adequately document the preparations. For example, method K-PA 0251I-HPLC2 outlines preparations of (b)(4) solutions and mobile phases with specific volumes. However, the only documentation within the laboratory journal includes the reagent lot numbers.

1.检测所用流动相与溶液的配制记录不充分。例如,方法 K-PA 0251I-HPLC2 规定了 (b)(4) 种溶液与流动相的配制及具体体积,但实验记录本中唯一的记录只有试剂批号。

2. Test sample and standard solutions used for assay, content uniformity, and degradation products do not document the steps used to prepare the solutions, including sonication, volumetric flasks, solutions used for dilution, and any subsequent dilutions. In addition, the content uniformity sample preparation requires (b)(4)(b)(4) The steps to this preparation are not documented.

2.用于含量、含量均匀度与降解产物测定的供试品溶液与对照品溶液,未记录配制步骤,包括超声、容量瓶、稀释用溶液以及后续各次稀释。此外,含量均匀度供试品溶液的配制需 (b)(4)(此处原文为大段脱敏)(b)(4)。该配制步骤未记录。

OBSERVATION 2

观察2:未彻底审查任何无法解释的差异,以及批次或其任何组分不符合规格的情形(211.192)

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

未能彻底审查任何无法解释的差异,以及批次或其任何组分不符合其任一规格的情形,无论该批次是否已经放行上市。

Specifically,

具体而言:

A. Deviation 200007918 was initiated during the compression of (b)(4) mg Batch (b)(4) due to tablets having a tendency to stick on the (b)(4) punch while filling container (b)(4). The following deficiencies were noted:

A.偏差 200007918 在压片 (b)(4) mg 批 (b)(4) 期间启动,原因是片剂在灌装容器 (b)(4) 时有粘附于 (b)(4) 冲头的倾向。发现以下缺陷:

1. The deviation stated that the error may occur sporadically from time to time, however no definitive root cause was identified which could have caused the issue, including but not limited to a dirty punch or a material issue.

1.该偏差称此错误可能偶发、时有时无;但未确定任何明确的根本原因,包括但不限于冲头不洁或物料问题。

2. The corrective action associated was to visually inspect containers (b)(4) which yielded an additional (b)(4) of rejected material. However, there was no heightened scrutiny of the batch to ensure that the batch did not result in any additional defective tablets after the cleaning of the tooling.

2.相关纠正措施是对容器 (b)(4) 进行目视检查,由此又发现了 (b)(4) 的剔除物料。但对本批未加严审查,以确保在清洁模具之后该批不再产生其他缺陷片。

3. The deviation stated that this had occurred within the last 12 months, however there was no further assessment performed to determine the number of deviations where this had occurred and if any additional corrective actions needed to be implemented to prevent the repetition of the deviation.

3.该偏差称此情况在过去12个月内发生过;但未进一步评估以确定发生此情况的偏差数量,也未评估是否需要实施其他纠正措施以防止偏差重复发生。

B. OOS investigations for (b)(4) mg Batch (b)(4) (Investigation 200008934) and (b)(4) mg Batch (b)(4) (Investigation 200010548) were initiated due to one sample being outside the specification for content uniformity. The OOS investigations concluded that two tablets must have been used instead of one since the values were doubled for that specific sample. However, there was no documented interview with the analyst to corroborate this root cause determination, nor does the test sample preparation documentation have adequate documentation to support this determination. In addition, the corrective action for both OOS investigations was to retrain the specific analyst which caused the issue. However, the corrective action did not extend to the remainder of the Quality Control personnel or address the specific root cause, nor was a preventive action adequately established to address the root cause identified for having two tablets during the content uniformity to prevent recurrence. In addition, based on the results of the OOS, the invalid result was isolated to the individual sample. The original (b)(4) results from the content uniformity test were invalidated without scientific justification.

B.(b)(4) mg 批 (b)(4)(调查 200008934)与 (b)(4) mg 批 (b)(4)(调查 200010548)的 OOS 调查,起因是一个样品的含量均匀度超出规格。两项 OOS 调查均得出结论:该样品数值翻倍,必是用了两片而不是一片。但没有与分析员的面谈记录来佐证这一根本原因判定,供试品配制记录也不足以支持该判定。此外,两项 OOS 调查的纠正措施均为重新培训当事分析员;该措施未扩展到其余质量控制人员,也未针对具体根本原因,更未就「含量均匀度检测中用了两片」这一已识别的根本原因建立充分的预防措施以防再发。此外,依据 OOS 结果,无效结果被限定于单个样品,含量均匀度检测的原始 (b)(4) 结果在无科学依据的情况下被判无效。

Observation 2A.2 was removed based on documentation within the associated deviation referenced in the observation.

【修正说明】基于本观察所涉偏差中的相关文件,Observation 2A.2(观察2 A 部分第2条)已被删除。原件以删除线划去该条,并在此处印有上述说明。

OBSERVATION 3

观察3:未建立并遵循设备(含器具)清洁与维护的书面程序(211.67(a))

Written procedures are not established and followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

对于药品生产、加工、包装或贮存所用设备(包括器具)的清洁与维护,未建立并遵循书面程序。

Specifically,

具体而言:

Equipment, tools, and ancillary containers used in the manufacture of drug products are not adequately labeled or maintained during manufacturing or cleaning. For example, during the walkthrough of the facility on 14Jul2025, I observed the following:

药品生产所用设备、工具与辅助容器,在生产或清洁期间未得到充分标识或维护。例如,2025年7月14日对厂区进行现场巡视时,我观察到以下情况:

1. Inspection of the (b)(4) (Room (b)(4)) equipment noted an apparent (b)(4) residue observed on the exterior of the (b)(4) (confirmed during the inspection as (b)(4) from the (b)(4) apparent (b)(4) residue remaining on the (b)(4) used for (b)(4) in exterior space outside of the (b)(4) but within the (b)(4), and an apparent (b)(4) residue on the (b)(4) gasket. This equipment was documented as clean following (b)(4) mg Batch (b)(4).

1.检查 (b)(4)(房间 (b)(4))设备时,注意到其外表面有明显 (b)(4) 残留(检查期间确认为来自 (b)(4) 的 (b)(4));用于 (b)(4) 的 (b)(4) 在 (b)(4) 外部、但位于 (b)(4) 之内的空间里留有明显 (b)(4) 残留;(b)(4) 垫圈上也有明显 (b)(4) 残留。该设备在 (b)(4) mg 批 (b)(4) 之后被记录为已清洁。

2. During the inspection of the tooling used for compression operations, I observed apparent (b)(4) residue remaining within the debossing of tablet punch set #7 (b)(4) (for (b)(4) mg tablets), after the documentation showed that the punches were cleaned. In addition, during the inspection of tablet punch set #(b)(4) (used for (b)(4) mg tablets), I observed at least one punch with an apparent dent and one punch with an apparent nick.

2.检查压片工序所用模具时,在文件显示冲头已清洁的情况下,我观察到 7 号压片冲模 (b)(4)(用于 (b)(4) mg 片)的凹字内仍有明显 (b)(4) 残留。此外,检查 (b)(4) 号压片冲模(用于 (b)(4) mg 片)时,我观察到至少一个冲头有明显凹痕、一个冲头有明显缺口。

Furthermore, the procedure related to the maintenance, cleaning, and inspection of compression tooling does not outline the instances when an investigation would need to be opened for defects observed at different inspection points throughout tooling inspection processes nor is it required to define the type of defects if found prior to when tooling is removed from use.

此外,与压片模具维护、清洁和检查有关的程序,未规定在模具检查流程各检查点发现缺陷时应在何种情形下启动调查,也未要求对停用前发现的缺陷类型作出界定。

来源:制药经理人 · mp.weixin.qq.com

事件后续 · 1

查看事件全部